Sector
PharmaceuticalsOpen
₹60.15Prev. Close
₹60.16Turnover(Lac.)
₹2,682.27Day's High
₹62.37Day's Low
₹59.9652 Week's High
₹100.952 Week's Low
₹42Book Value
₹21.73Face Value
₹2Mkt Cap (₹ Cr.)
3,369.92P/E
33.24EPS
1.85Divi. Yield
0.33With this approval, Morepen Laboratories aims to strengthen its presence in China, which is one of the world’s largest pharmaceutical markets.
Developed from scratch, this drug offers an inexpensive and superior alternative to current treatments, making it accessible to hundreds of millions of patients.
Here are some of the stocks that may see significant price movement today: Tata Motors, ITC, Kalyan Jewellers, etc.
Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 102.23 | 102.23 | 121.81 | 133.71 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 786.8 | 677.89 | 476.36 | 311.26 |
Net Worth | 889.03 | 780.12 | 598.17 | 444.97 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Revenue | 1,112.42 | 791.98 | 560.83 | 547.5 |
yoy growth (%) | 40.45 | 41.21 | 2.43 | 21 |
Raw materials | -736.61 | -521.08 | -342.59 | -335.73 |
As % of sales | 66.21 | 65.79 | 61.08 | 61.32 |
Employee costs | -123.2 | -98.07 | -68.21 | -60.79 |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Profit before tax | 94.24 | 37.48 | 26.11 | 23.16 |
Depreciation | -28.11 | -34.43 | -33.39 | -33.56 |
Tax paid | 0 | -5.14 | 0 | 0 |
Working capital | -26.96 | 124.59 | -1.66 | 17.45 |
Other operating items |
Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 40.45 | 41.21 | 2.43 | 21 |
Op profit growth | 74.31 | 6.96 | -0.35 | -5.78 |
EBIT growth | 143.44 | 29.72 | -0.75 | 0.61 |
Net profit growth | 191.49 | 23.8 | 12.72 | 46.83 |
Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|---|
Gross Sales | 1,811.58 | 1,690.43 | 1,417.53 | 1,546.83 | 1,188.06 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 1,811.58 | 1,690.43 | 1,417.53 | 1,546.83 | 1,188.06 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 18.36 | 13.97 | 6.13 | 10.31 | 12.07 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,647.6 | 92.29 | 3,95,254.45 | 2,000.46 | 0.97 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,493 | 78.03 | 1,72,374.06 | 667 | 0.46 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,484 | 24.33 | 1,19,795.19 | 1,485.4 | 1.08 | 4,254.47 | 397.41 |
Dr Reddys Laboratories Ltd DRREDDY | 1,326.1 | 20.69 | 1,10,689.83 | 1,200.7 | 0.6 | 5,546.3 | 345.79 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,164 | 56.27 | 1,07,213.01 | 474 | 1.01 | 2,385 | 224.33 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Managing Director
Sushil Suri
Company Sec. & Compli. Officer
Vipul Kumar Srivatava
Whole-time Director
Sanjay Suri
Non-Exec. & Independent Dir.
Praveen Kumar Dutt
Non-Exec. & Independent Dir.
Savita
Independent Director
Sharad Jain
Morepen Village,
Nalagarh Road Near Baddi,
Himachal Pradesh - 173205
Tel: 91-01795-276201-03
Website: http://www.morepen.com
Email: investors@morepen.com
T-34 2nd Floor,
Okhla Industrial Are, Phase II,
New Delhi - 110020
Tel: 91-011-26387281/83
Website: www.masserv.com
Email: info@massere.com
Summary
Morepen Laboratories Limited is an India-based pharmaceutical company. Its products include Loratadine, Montelukast Sodium, Atorvastatin Calcium and Sultamicillin. The company markets formulation prod...
Read More
Reports by Morepen Laboratories Ltd
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.